Aptorum (APM)

Company Profile

Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through programs such as the systematic screening of existing approved drug molecules and microbiome-based research platform for treatments of metabolic diseases. Aptorum also has projects focused on microbiome research and the commercialization of a natural supplement product targeted for women undergoing menopause and experiencing related symptoms.

Company profile

Ticker

APM

Exchange

NASDAQ

Website

www.aptorumgroup.com

CEO

Ian Huen

Incorporated

Cayman Islands

Location

United Kingdom

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001734005

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

APM stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6-K

Report of Foreign Private Issuer

24 Jan 23

6-K

Aptorum Group Announces 1-for-10 Reverse Stock Split

20 Jan 23

EFFECT

Notice of effectiveness

20 Jan 23

20-F/A

2021 FY

Annual report (foreign) (amended)

17 Jan 23

6-K

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

22 Dec 22

F-3

Shelf registration (foreign)

19 Dec 22

6-K

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

16 Dec 22

6-K

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

9 Dec 22

6-K

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

18 Nov 22

6-K

Report of Foreign Private Issuer

8 Nov 22

Latest ownership filings

View all

SC 13G

Hudson Bay Capital Management LP

Hudson Bay Capital Management LP

Financial summary

Financial statements Chart APM financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Aptorum earnings reports.

Institutional ownership, Q2 2022

APM institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	10	9	+11.1%
Opened positions	2	2	–
Closed positions	1	6	-83.3%
Increased positions	6	5	+20.0%
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	455.81 mm	455.97 mm	-0.0%
Total shares	165.45 mm	165.43 mm	+0.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Huen Ian Chung Yuen	164.86 mm	$455.01 mm	0.0%
Geode Capital Management	332.77 k	$455.00 k	+1.8%
MS Morgan Stanley	87.30 k	$120.00 k	+9.0%
Redmond Asset Management	62.79 k	$86.00 k	0.0%
Schonfeld Strategic Advisors	44.80 k	$62.00 k	+0.7%
Millennium Management	21.42 k	$29.00 k	+11.1%
Susquehanna International	18.10 k	$25.00 k	NEW
Two Sigma Securities	10.25 k	$14.00 k	NEW
UBS UBS Group AG - Registered Shares	6.71 k	$9.00 k	+231.6%
Tower Research Capital	3.11 k	$4.00 k	+215.9%

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	0.00	-36.00 k	EXIT
Susquehanna International	18.10 k	+18.10 k	NEW
Two Sigma Securities	10.25 k	+10.25 k	NEW
MS Morgan Stanley	87.30 k	+7.20 k	+9.0%
Geode Capital Management	332.77 k	+5.92 k	+1.8%
UBS UBS Group AG - Registered Shares	6.71 k	+4.69 k	+231.6%
Millennium Management	21.42 k	+2.13 k	+11.1%
Tower Research Capital	3.11 k	+2.13 k	+215.9%
Schonfeld Strategic Advisors	44.80 k	+300.00	+0.7%
Proequities	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.